⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885926 | 0.70 | L3MBTL1 (0.32) | — | |
| SCHEMBL8007026 | 0.69 | — | — | |
| SCHEMBL8654177 | 0.69 | — | — | |
| SCHEMBL3976896 | 0.69 | — | — | |
| SCHEMBL11656536 | 0.64 | — | — | |
| SCHEMBL3377459 | 0.60 | — | — | |
| SCHEMBL3889040 | 0.59 | — | — | |
| SCHEMBL1573519 | 0.58 | — | — | |
| SCHEMBL10519972 | 0.58 | — | — | |
| SCHEMBL237154 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114262344-A | Charged linkers and their use in conjugation reactions | 杭州多禧生物科技有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-112125929-A | Hydrophilic linkers for coupling | 杭州多禧生物科技有限公司 | 2020-12-25 | — | — | CN | claimed |
| CN-110709386-A | Bicyclic heteroaryl derivatives, their preparation and use | 凯瑞康宁生物工程（武汉）有限公司 | 2020-01-17 | — | — | CN | claimed |
| CN-115956081-A | Imidazopyridazine compounds having activity as ALK2 inhibitors | 因赛特公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115803062-A | Antibodies to trophoblast cell surface antigen 2 (TROP-2) | 博泰康医药公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-109219616-B | GM-CSF antibodies and uses thereof | 天境生物科技(杭州)有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-109715821-B | Antigen binding proteins that bind to PD-L1 | 索伦托药业有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-114929246-A | Use of iodide compounds for the treatment and prevention of chemotherapy-associated cachexia and cardiotoxicity | 法拉第制药公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114555790-A | WT-1 specific T cell immunotherapy | 弗雷德哈钦森癌症研究中心 | 2022-05-27 | — | — | CN | disclosed |
| CN-114262344-A | Charged linkers and their use in conjugation reactions | 杭州多禧生物科技有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-108778477-B | Bifurcated mixer and methods of use and manufacture thereof | 不列颠哥伦比亚大学 | 2022-02-25 | — | — | CN | disclosed |
| CN-111655247-A | Enhancing T cell function and treating T cell dysfunction disorders with a combination of a LSD inhibitor and a PD1 binding antagonist | 艾比克斯治疗私人有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-111139256-A | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptors | 诺华股份有限公司 | 2020-05-12 | — | — | CN | disclosed |
| CN-105358576-B | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptors | 诺华股份有限公司 | 2020-05-05 | — | — | CN | disclosed |
| CN-111065410-A | Methods for improving adoptive cell therapy | 弗雷德哈钦森癌症研究中心 | 2020-04-24 | — | — | CN | disclosed |
| CN-111051349-A | STREP-TAG specific chimeric receptor and application thereof | 弗雷德哈钦森癌症研究中心 | 2020-04-21 | — | — | CN | disclosed |
| CN-110891549-A | Method for improving solubility and bioavailability of therapeutic agents | 玛亚实验室公司 | 2020-03-17 | — | — | CN | disclosed |
| CN-110891975-A | anti-PD-L1 antibodies and uses thereof | 天境生物科技(上海)有限公司 | 2020-03-17 | — | — | CN | disclosed |
| CN-104945382-B | Substituted piperidines that increase p53 activity and uses thereof | 默沙东公司 | 2020-02-07 | — | — | CN | disclosed |
| CN-110582299-A | High affinity MAGE-A1 specific TCRs and uses thereof | 弗雷德哈钦森癌症研究中心 | 2019-12-17 | — | — | CN | disclosed |